REGENXBIO Inc. (NASDAQ:RGNX) Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $50.05, for a total transaction of $750,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of REGENXBIO opened at $48.70 on Friday, MarketBeat Ratings reports. REGENXBIO Inc. has a fifty-two week low of $16.30 and a fifty-two week high of $51.20. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 35.59, a price-to-earnings-growth ratio of 25.70 and a beta of -1.23.
REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported $3.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.00 by $2.04. REGENXBIO had a return on equity of 23.27% and a net margin of 37.28%. The business had revenue of $132.39 million during the quarter, compared to analyst estimates of $80.00 million. equities analysts forecast that REGENXBIO Inc. will post 0.61 earnings per share for the current year.
Large investors have recently modified their holdings of the business. Bayesian Capital Management LP purchased a new position in REGENXBIO in the 1st quarter worth about $220,000. Trexquant Investment LP purchased a new position in REGENXBIO in the 1st quarter worth about $233,000. Cubist Systematic Strategies LLC purchased a new position in REGENXBIO in the 1st quarter worth about $241,000. Teacher Retirement System of Texas purchased a new position in REGENXBIO in the 4th quarter worth about $302,000. Finally, Element Capital Management LLC purchased a new position in REGENXBIO in the 1st quarter worth about $281,000. 67.42% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently issued reports on RGNX. TheStreet upgraded shares of REGENXBIO from a “d+” rating to a “c” rating in a research note on Friday, May 11th. ValuEngine upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. Raymond James set a $45.00 price target on shares of REGENXBIO and gave the stock a “buy” rating in a research note on Tuesday, May 8th. Barclays reiterated an “overweight” rating and issued a $48.00 price target (up previously from $38.00) on shares of REGENXBIO in a research note on Wednesday, May 9th. Finally, BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $43.25.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.